Cargando…
COVID-19 outcomes in giant cell arteritis and polymyalgia rheumatica versus rheumatoid arthritis: A national, multicenter, cohort study
OBJECTIVES: To determine whether giant cell arteritis and polymyalgia rheumatica (GCA/PMR) represent independent risk factors for worse outcomes in COVID-19. METHODS: Observational, national, French, multicenter cohort (NCT04353609) comprising patients aged ≥18 years with confirmed diagnoses of eith...
Autores principales: | Vieira, Matheus, Comarmond, Cloé, Labreuche, Julien, Mirouse, Adrien, Saadoun, David, Richez, Christophe, Flipo, René-Marc, Hachulla, Eric, Drumez, Elodie, Cacoub, Patrice |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9296684/ https://www.ncbi.nlm.nih.gov/pubmed/35926375 http://dx.doi.org/10.1016/j.jaut.2022.102868 |
Ejemplares similares
-
Is Tocilizumab Effective and Safe in Polymyalgia Rheumatica and Giant-Cell Arteritis With Polymyalgia Rheumatica?
por: Farinango, Michelle, et al.
Publicado: (2022) -
Optimal management of giant cell arteritis and polymyalgia rheumatica
por: Charlton, Rodger
Publicado: (2012) -
Genetic epidemiology: Giant cell arteritis and polymyalgia rheumatica
por: Gonzalez-Gay, Miguel A
Publicado: (2001) -
Giant Cell Arteritis and Polymyalgia Rheumatica: 2016 Update
por: Nesher, Gideon, et al.
Publicado: (2016) -
Liver involvement in polymyalgia rheumatica and giant cell arteritis
por: Hysa, Elvis, et al.
Publicado: (2020)